Head-to-head evidence
NNG-DEPO vs rESP
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: Erythropoietin receptor (EPO-R) · full Chronic Kidney Disease pipeline
NNG-DEPO · Stimus
Developed by Nanogen Pharmaceutical Biotechnology
NCT05585645 · Phase 3 · completed
The trial was randomized, double-blind, and actively controlled with Aranesp, enrolling 214 participants. However, its primary endpoint was a hemoglobin change measure rather than a hard clinical outcome, and no primary comparison results are available.
rESP
Developed by Shenyang Sunshine Pharmaceutical
NCT05211167 · Phase 3 · status unknown
This is a randomized, active-controlled Phase 3 trial with an adequately sized enrollment comparing the study drug against a standard recombinant erythropoietin, using change in hemoglobin, the measure that defines the anemia being treated, as its primary endpoint. However, the trial was not blinded, and results have not been posted yet. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: NNG-DEPO's landscape · rESP's landscape